Role of Primary Tumour Resection and Addition of Bevacizumab to Chemotherapy in the Management of Advanced Colorectal Cancer with Inoperable Metastasis: A Retrospective Analysis
DOI:
https://doi.org/10.6000/1927-7229.2013.02.04.3Keywords:
Primary Tumour Resection, Advanced Colorectal Cancer, Metastases, Survival, Bevacizumab.Abstract
Purpose:To analyze the impact of primary tumour resection on treatment outcomes in patients with advanced colorectal cancer (CRC) and inoperable metastases at diagnosis in combination with optimal systemic therapy.
Methods:A retrospective study was carried out in four hospitals in Valencia (Spain) including all consecutive patients diagnosed between 1/2009 and 12/2010 of advanced CRC with inoperable metastasis and treated with a fluoropyrimidine and oxaliplatin combination chemotherapy regimens with or without bevacizumab (B). Treatment outcomes were compared between patients undergoing or not primary tumour resection.
Results:A total of 112 patients met inclusion criteria: 62 patients underwent resection of the primary tumour (Group 1) and 50 were treated with exclusive chemotherapy (Group 2). Globally, patients in group 2 presented more disfavorable characteristics. Forty-five (72%) and 31 (62%) patients received chemotherapy with bevacizumab respectively. Overallresponse rate(ORR) were 67% in Group 1 and 56% in Group 2. There were no statistically significant differences between the two groups in progression free survival (PFS) (12 vs. 10 months; p =0.11) and overall survival (OS) (27 vs. 22 months; p 0.1). B regimens increased ORR (73% vs. 42%; p = 0.003) and PFS (12 vs. 11 months; p = 0.019) but not OS. Complications were higher in the group of patients without primary tumour resection, particularly when associated to B regimens.
Conclusions:Primary tumour resection offers no survival gain for patients with advanced CRC and inoperable metastases. Benefits of adding Bevacizumab to standard chemotherapy were similar in both groups, but it increases the risk of complications in non-resected patients.
References
Surveillance, Epidemiology and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 17 Regs Limited-Use, Nov 2006 Sub (1973-2004 varying), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission. Accessed May 2013.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, Eds. AJCC cancer staging manual (7th ed). New York, NY: Springer 2010; p. 143.
Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012; 62(1): 10-29. http://dx.doi.org/10.3322/caac.20138
Bleiberg H. Role of chemotherapy for advanced colorrectal cancer. New oportunities. Semin Oncol 1996; 23(1 Suppl 3): 42-50.
De Gramont A, Vignoud J, Tournigand C, Louvet C, André T, Varette C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hours continuous infusion in preatreated metastático colorrectal cancer. Eur J Cancer 1997; 33(2): 214-9. http://dx.doi.org/10.1016/S0959-8049(96)00370-X
Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001; 280(6): C1358-66.
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9(6): 669-76. http://dx.doi.org/10.1038/nm0603-669
Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7(9): 987-9. http://dx.doi.org/10.1038/nm0901-987
Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23(16): 3706-12. http://dx.doi.org/10.1200/JCO.2005.00.232
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335-42. http://dx.doi.org/10.1056/NEJMoa032691
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25(12): 1539-44. http://dx.doi.org/10.1200/JCO.2006.09.6305
Saltz L, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26(12): 2013-9. http://dx.doi.org/10.1200/JCO.2007.14.9930
Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, Grant DR, et al. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 2006; 202(3): 468-75. http://dx.doi.org/10.1016/j.jamcollsurg.2005.11.008
Galizia G, Lieto E, Orditura M, Castellano P, Imperatore V, Pinto M, et al. First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. Arch Surg 2008; 143(4): 352-8. http://dx.doi.org/10.1001/archsurg.143.4.352
Cook AD, Single R, McCahill LE. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Ann Surg Oncol 2005; 12(8): 637-45. http://dx.doi.org/10.1245/ASO.2005.06.012
Konyalian VR, Rosing DK, Haukoos JS, Dixon MR, Sinow R, Bhaheetharan S, et al. The role of primary tumour resection in patients with stage IV colorectal cancer. Colorectal Dis 2007; 9(5): 430-7. http://dx.doi.org/10.1111/j.1463-1318.2007.01161.x
Karoui M, Roudot-Thoraval F, Mesli F, Mitry E, Aparicio T, Des Guetz G, et al. Primary colectomy in patients with stage IV colon cancer and unresectable distant metastases improves overall survival: results of a multicentric study. Dis Colon Rectum 2011; 54(8): 930-8. http://dx.doi.org/10.1097/DCR.0b013e31821cced0
Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD, et al. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol 1999; 6(7): 651-7. http://dx.doi.org/10.1007/s10434-999-0651-x
Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol 2005; 89(4): 211-7. http://dx.doi.org/10.1002/jso.20196
Karoui M, Koubaa W, Delbaldo C, Charachon A, Laurent A, Piedbois P, et al. Chemotherapy has also an effect on primary tumor in colon carcinoma. Ann Surg Oncol 2008; 15(12): 3440-6. http://dx.doi.org/10.1245/s10434-008-0167-9
McCahill L, Yothers GA, Sharif S, Petrelli NJ, Lai LL, Bechar N, et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastático colon cancer and an intact asymptomatic colon cancer: definitive análisis of NSABP trial C-10. J Clin Oncol 2012; 30(26): 3223-8. http://dx.doi.org/10.1200/JCO.2012.42.4044
Venderbosch S, Wilt JH, Teerenstra S, Loosveld OJ, van Bochove A, Sinnige HA, et al. Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective análisis of two randomized Studies and a review of the literature. Ann Surg Oncol 2011; 18(12): 3252-60. http://dx.doi.org/10.1245/s10434-011-1951-5
Faron M, Bourredjem A, Pignon JP, Bouche O, Douillard JY, Adenis A, et al. Impact on survival of primary tumor resection in patients with colorrectal cancer and unresectable metastasis: pooled análisis of individual patients´ data from four randomized trials. J Clin Oncol 2012; 30(15suppl): Abstract 3507.
Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009; 27(20): 3379-84. http://dx.doi.org/10.1200/JCO.2008.20.9817
Cirocchi R, Trastulli S, Abraha I, Vettoretto N, Boselli C, Montedori A, et al. Non-resection versus resection for an asyptomatic primary tumour in patients with unresectable stage IV colorectal cancer. Cochrane Database Syst Rev 2012; 8: CD008997.
Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol 2008; 19(11): 1829-35. http://dx.doi.org/10.1093/annonc/mdn398
Kozloff M, Yood MU, Berlin H, Flynn PJ, Kabbinavar FF, Purdie DM, et al. Clinical Outcomes associated with bevacizumab-containing treatment of metastático colorectal cancer: The BRITE Observational Cohort Study. Oncologist 2009; 14(9): 862-70. http://dx.doi.org/10.1634/theoncologist.2009-0071
Ruo L, Gougoutas C, Paty PB, Guillem JG, Cohen AM, Wong WD. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg 2003; 196(5): 722-8. http://dx.doi.org/10.1016/S1072-7515(03)00136-4
Downloads
Published
Issue
Section
How to Cite
Similar Articles
- Paola Fernanda Fedatto, Thais Inácio de Carvalho, Jaqueline Carvalho de Oliveir, David Santos Marco Antônio, Julia Alejandra Pezuk, Daniela Pretti da Cunha Tirapell, Omar Féres, osé Joaquim Ribeiro da Rocha, Carlos Alberto Scrideli, Luiz Gonzaga Tone, María Sol Brassesco, MiR-708-5p as a Predictive Marker of Colorectal Cancer Prognosis , Journal of Analytical Oncology: Vol. 5 No. 1 (2016)
- Sven Wenske , Philippa Cheetham, Aaron E. Katz, Clinical and Biochemical Outcomes of High-Risk Prostate Cancer Patients treated with Third Generation Prostate Cryosurgery , Journal of Analytical Oncology: Vol. 2 No. 2 (2013)
- Sergio Vázquez, María José Villanueva, José Luis Fírvida, Begoña Campos, Martín Lázaro, Gerardo Huidobro, María del Carmen Areses, Natalia Fernández, Marta Covela , Joaquín Casal, Erlotinib as Second-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors , Journal of Analytical Oncology: Vol. 4 No. 3 (2015)
- Martin Czejka, Andreas Kiss, Eva Ostermann, Johannes Schueller, Mansoor Ahmed, Najia Mansoor, Tasneem Ahmad, Metabolic Activation and Inactivation of Irinotecan when Combined with the Human Monoclonal Antibody Bevacizumab , Journal of Analytical Oncology: Vol. 2 No. 4 (2013)
- Paola Castro-Garcia, Carmen Gil-Gas, Paloma Honrubia-Gómez, Carmen Belen Alvarez-Simón, Jesús-José Ferré-Fernández, Francisco Sánchez-Sánchez, Jose Luis Sánchez-Sánchez, Jose Mª Garcia-Bueno, Sebastiá Sabater, Guadalupe Aparicio, Luis Miguel Antón-Aparicio, Carmen Ramírez-Castillejo, C-Terminal-PEDF Reduces IC50 Doses and Chemoresistant Population of CD133 and BCRP1-Positve Cancer Stem Like Cells , Journal of Analytical Oncology: Vol. 2 No. 4 (2013)
- Simona Di Francesco, Raffaele L. Tenaglia, Metabolic Alterations, Vascular Disease and Advanced Prostate Cancer: New Players for Metastatic Advanced Prostate Cancer? , Journal of Analytical Oncology: Vol. 3 No. 1 (2014)
- Mai Ashraf Talaat, The Influence of Radiation Therapy on Dental Implantation in Head and Neck Cancer Patients , Journal of Analytical Oncology: Vol. 12 (2023)
- Miklos L. Auber, Sijin Wen, Francesca Farran, Gerald M. Higa, Survival Outcomes in High-Risk, Resected Colorectal Cancer with and without Maintenance Therapy , Journal of Analytical Oncology: Vol. 12 (2023)
- Maria Fernanda Evangelista Simões, Clarissa Maria de Cerqueira Mathias, Oddone Freitas Melro Braghiroli, Eldsamira da Silva Mascarenhas Schettini Sobrinho , Subacute Paraneoplastic Cerebellar Degeneration in an Advanced Small Cell Lung Cancer Patient: Case Report and Literature Review , Journal of Analytical Oncology: Vol. 4 No. 2 (2015)
- Cardile Venera , Avola Rosanna, C.E. Graziano Adriana, Madrid Alejandro, Russo Alessandra, Boldine Activates Intrinsic Apoptotic Pathway in DU-145 Androgen-Independent Prostate Cancer Cell Line , Journal of Analytical Oncology: Vol. 8 (2019)
You may also start an advanced similarity search for this article.
Most read articles by the same author(s)
- Pedro Salinas Hernández, Rafael Trujillo Vilchez, Antonio Arriví García-Ramos, Rosana Grande Ladron de Guevara, Angeles Rodríguez Jaraiz, Pedro Gallurt Moreira, Jose Maria Vieitez de Prado, Miguel Ruiz López de Tejada, Antonio Irigoyen Medina, Juan Manuel Campos Cervera, Juan Carlos Cámara Vicario, Uriel Bohn Sarmiento, Pedro López Tendero, Juan Domingo Alonso Lajara, Ana León Carbonero, Marisa García de Paredes, Juan de Alvaro Liaño, Asunción Juarez Marroquí, Luis López Gómez , Diego Soto de Prado Otero, Bevacizumab Plus Chemotherapy as First-Line Treatment for Patients with Metastatic Colorectal Cancer: Results from a Spanish Observational Study , Journal of Analytical Oncology: Vol. 2 No. 3 (2013)